阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALNY 阿尔尼拉姆制药公司

未开盘 08-12 16:00:00 EDT

223.95

+2.75

+1.24%

盘后223.00

-0.95-0.42%

19:55 EDT

最高224.66	最低219.00	成交量162.13万
今开219.00	昨收221.20	日振幅2.56%
总市值298.81亿	流通市值298.21亿	总股本1.33亿
成交额3.62亿	换手率1.22%	流通股本1.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"阿尔尼拉姆制药公司","latestPrice":223.95,"timestamp":1786564800000,"preClose":221.2,"halted":0,"volume":1621305,"hourTrading":{"tag":"盘后","latestPrice":223,"preClose":223.95,"latestTime":"19:55 EDT","volume":246774,"amount":55264683.408,"timestamp":1786578911157,"change":-0.95,"changeRate":-0.004242,"amplitude":0.00896},"delay":0,"changeRate":0.012432188065099457,"floatShares":133157589,"shares":133427910,"eps":5.619342,"marketStatus":"未开盘","change":2.75,"latestTime":"08-12 16:00:00 EDT","open":219,"high":224.66,"low":219,"amount":361946824.18965,"amplitude":0.025588,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":5.619342,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786608000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":221.2,"preHourTrading":{"tag":"盘前","latestPrice":220.35,"preClose":221.2,"latestTime":"09:29 EDT","volume":988,"amount":217905.75144,"timestamp":1786541343295,"change":-0.85,"changeRate":-0.003843,"amplitude":0.049933},"postHourTrading":{"tag":"盘后","latestPrice":223,"preClose":223.95,"latestTime":"19:55 EDT","volume":246774,"amount":55264683.408,"timestamp":1786578911157,"change":-0.95,"changeRate":-0.004242,"amplitude":0.00896},"volumeRatio":0.845472,"impliedVol":0.4324,"impliedVolPercentile":0.3904},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"1186363034","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.04%，Q2指引下调后持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1186363034","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186363034?lang=zh_cn&edition=full","pubTime":"2026-08-07 03:11","pubTimestamp":1786043490,"startTime":"0","endTime":"0","summary":"8月7日，阿尔尼拉姆制药公司盘中下跌5.04%，报217.2美元/股，成交额2.71亿美元。财报公布后股价单日暴跌约28%，此后虽有技术性反弹，但市场对增长斜率放缓的担忧仍在消化中。RBC将目标价从445美元大幅下调至350美元，Stifel下调至318美元，均维持正面评级但承认短期不确定性上升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169468558","title":"异动解读｜阿尔尼拉姆制药公司盘中上涨5.47%，多家机构维持看好评级称此前跌幅过度","url":"https://stock-news.laohu8.com/highlight/detail?id=1169468558","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169468558?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:07","pubTimestamp":1785766037,"startTime":"0","endTime":"0","summary":"8月3日，阿尔尼拉姆制药公司盘中上涨5.47%，报218.375美元/股，成交额1.73亿美元。此前公司因Q2营收不及预期及全年指引下调，股价在7月30日单日暴跌逾28%。Stifel同期维持买入评级，目标价调至318美元。公司Q2调整后每股收益1.84美元超预期18.71%，同比增长475%，管理层重申至2030年总收入复合增速超25%的目标。多家机构集体维持正面评级，缓解了市场恐慌情绪，推动股价技术性反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿尔尼拉姆制药公司盘中上涨5.47%，多家机构维持看好评级称此前跌幅过度","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158920980","title":"异动解读 | 阿尔尼拉姆制药公司盘中大跌27.20%，全年产品收入指引下调叠加营收不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1158920980","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158920980?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:14","pubTimestamp":1785420870,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司今日盘中股价大幅下挫27.20%，引发市场高度关注。更为关键的是，公司将2026年全年产品净收入指引从此前的49亿至53亿美元下调至47亿至51亿美元，这一调整直接触发了市场的恐慌性抛售。此外，美银证券此前已对核心产品Amvuttra的长期净价格侵蚀表达担忧，预计竞争压力将持续至2031年，并将目标价从460美元下调至410美元。营收不及预期与全年指引下调形成共振，进一步验证了市场对竞争格局恶化的担忧，导致股价承受显著抛压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180271424","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌20.29%，Q2营收不及预期叠加全年指引下调","url":"https://stock-news.laohu8.com/highlight/detail?id=1180271424","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180271424?lang=zh_cn&edition=full","pubTime":"2026-07-30 21:41","pubTimestamp":1785418862,"startTime":"0","endTime":"0","summary":"7月30日，阿尔尼拉姆制药公司盘中下跌20.29%，报218.605美元/股，成交额1.84亿美元。消息面上，公司发布第二季度财报：调整后每股收益1.84美元，同比大幅增长；营收12.91亿美元，低于市场一致预期的13.2亿美元。更为关键的是，公司将全年净产品收入指引由此前的49亿至53亿美元下调至47亿至51亿美元，引发市场对增长放缓的担忧。营收不及预期与指引下调共振，验证了市场对竞争格局恶化的担忧，导致股价承受显著抛压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175560090","title":"阿尔尼拉姆制药公司公布2026年第二季度财报，并重点回顾近期阶段性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1175560090","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175560090?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:02","pubTimestamp":1785412965,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司于近日正式披露了2026年第二季度的财务业绩。与此同时，该公司还着重梳理了在过去一段时间内所取得的各项关键进展。在回顾近期发展时，阿尔尼拉姆强调，其针对多项罕见病及常见疾病的RNAi疗法研究已进入新的里程碑阶段。总体而言，这段时期标志着阿尔尼拉姆在科学探索与商业价值实现上均迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0114720955.EUR","LU0882574055.USD","LU0109394709.USD","LU0889565916.HKD","BK4548","ALNY","PBE","LU0320765992.SGD","GNMX","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193228171","title":"异动解读 | 财报发布日遭遇高预期与竞争担忧，阿尔尼拉姆制药盘前大跌7.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193228171","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193228171?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:02","pubTimestamp":1785412954,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司今日盘前大跌7.45%，报265.28美元/股，成交额43.81万美元，引发市场关注。今日为公司第二季度财报发布日（盘前），市场此前对本季度业绩抱有较高预期。美银证券此前指出，本季度业绩将决定全年收入落在指引区间的何处，以及管理层是否进一步调整指引。此外，美银证券对Amvuttra的长期净价格侵蚀表达担忧，预计竞争压力将持续至2031年，并将目标价从460美元下调至410美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130355531","title":"异动解读｜阿尔尼拉姆制药公司盘前下跌7.45%，财报发布日遭遇市场卖压","url":"https://stock-news.laohu8.com/highlight/detail?id=1130355531","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130355531?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:01","pubTimestamp":1785412918,"startTime":"0","endTime":"0","summary":"7月30日，阿尔尼拉姆制药公司盘前下跌7.45%，报265.28美元/股，成交额43.81万美元。当日为公司第二季度财报发布日（盘前），市场此前对本季度业绩抱有较高预期，一致预期营收约13.20亿美元，调整后每股收益约1.59美元。消息面上，美银证券此前指出，本季度业绩将决定全年收入落在指引区间的何处，以及管理层是否进一步调整指引。该机构同时对Amvuttra长期净价格侵蚀表达担忧，预计竞争压力将持续至2031年，并将目标价从460美元下调至410美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173260071","title":"财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增70.56%，机构观点呈偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1173260071","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173260071?lang=zh_cn&edition=full","pubTime":"2026-07-23 10:14","pubTimestamp":1784772841,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司将于2026年07月30日发布最新季度财报，市场关注营收与盈利弹性及核心产品驱动下的增长质量。市场一致预期本季度阿尔尼拉姆制药公司营收为13.20亿美元，同比增长70.56%；毛利率预测未披露；净利润或净利率预测未披露；调整后每股收益预计为1.59美元，同比增长410.78%；息税前利润预计为2.86亿美元，同比增长501.98%。公司当前主营由“产品”“合同”“许可协议”构成，上季度“产品”收入10.36亿美元占比88.77%，体现核心商业化产品放量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增70.56%，机构观点呈偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129095578","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.04%，报268.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129095578","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129095578?lang=zh_cn&edition=full","pubTime":"2026-07-18 02:35","pubTimestamp":1784313355,"startTime":"0","endTime":"0","summary":"7月17日，阿尔尼拉姆制药公司盘中下跌5.04%，报268.89美元/股，成交额1.74亿美元。阿尔尼拉姆制药公司所在的生物科技行业中，整体表现偏弱，个股中，艾伯维公司涨0.61%，安进跌2.44%，吉利德科学跌1.10%，福泰制药跌0.40%，再生元制药公司跌0.92%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125707751","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.29%，报280.705美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125707751","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125707751?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:16","pubTimestamp":1783952164,"startTime":"0","endTime":"0","summary":"7月13日，阿尔尼拉姆制药公司盘中下跌5.29%，报280.705美元/股，成交额1.15亿美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股中，艾吉纳斯公司涨142.68%，Q32 Bio Inc.涨61.6%，Moderna涨0.43%，Nuvalent涨0.04%，艾伯维公司跌0.85%。阿尔尼拉姆制药公司是一家基于RNA干扰（RNAi）技术的生物制药公司，通过RNAi选择性沉默特定基因以治疗多种人类疾病，核心产品包括用于转甲状腺素蛋白淀粉样变性的Amvuttra及Onpattro等。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106574639","title":"异动解读｜阿尔尼拉姆制药公司盘中下跌5.08%，报296.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106574639","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106574639?lang=zh_cn&edition=full","pubTime":"2026-07-11 00:51","pubTimestamp":1783702305,"startTime":"0","endTime":"0","summary":"7月11日，阿尔尼拉姆制药公司盘中下跌5.08%，报296.89美元/股，成交额3.34亿美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股中，艾伯维公司跌1.42%，Ionis Pharmaceuticals跌8.01%，Moderna跌11.25%，吉利德科学跌3.67%，BridgeBio Pharma跌4.18%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187899712","title":"异动解读｜阿尔尼拉姆制药公司盘中上涨15.34%，竞争对手阿斯利康心脏病后期试验失败提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1187899712","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187899712?lang=zh_cn&edition=full","pubTime":"2026-07-09 21:58","pubTimestamp":1783605534,"startTime":"0","endTime":"0","summary":"7月9日，阿尔尼拉姆制药公司盘中上涨15.34%，报361.795美元/股，成交额6.31亿美元。消息面上，竞争对手阿斯利康与Ionis Pharmaceuticals合作开发的神经疾病治疗药物Wainua，在一项针对特定心脏病患者的后期临床研究中未能达到主要终点。市场认为该试验失利为阿尔尼拉姆旗下同适应症产品扫清了潜在竞争障碍。基本面方面，阿尔尼拉姆核心产品Amvuttra上一季度净产品收入约8.27亿美元，商业化能力已获市场验证。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167833053","title":"阿尔尼拉姆制药公司股价大涨15.5%，因阿斯利康神经疾病药物Wainua心脏病后期试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=1167833053","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167833053?lang=zh_cn&edition=full","pubTime":"2026-07-09 21:35","pubTimestamp":1783604157,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司股价飙升超过15%，这一显著涨幅源于其竞争对手阿斯利康的一款药物在关键临床试验中遭遇挫折。阿斯利康与合作伙伴Ionis Pharmaceuticals开发的神经疾病治疗药物Wainua，在一项针对特定心脏病患者的后期研究中未能达到主要目标。\n市场对此反应迅速，投资者将目光投向了阿尔尼拉姆。该公司拥有针对相似适应症的在研药物，此次竞争对手的试验失利，被广泛视为为阿尔尼拉姆的产品扫清了潜在的竞争障碍，或至少推迟了其面临的直接市场挑战。这一事件凸显了生物制药领域激烈的竞争动态，单一临床结果足以引发相关公司市场估值的剧烈波动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4548","LU0320765992.SGD","BK4139","PBE","BK4588","LU0882574055.USD","LU0109394709.USD","LU0114720955.EUR","ALNY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105086619","title":"异动解读｜阿尔尼拉姆制药公司盘前上涨6.11%，报336.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105086619","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105086619?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:02","pubTimestamp":1783584167,"startTime":"0","endTime":"0","summary":"7月9日，阿尔尼拉姆制药公司盘前上涨6.11%，报336.95美元/股，成交额15.37万美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股中，艾伯维公司涨0%，福泰制药涨0.39%，吉利德科学跌0.38%，安进跌0.48%，再生元制药公司涨0%。阿尔尼拉姆制药公司是一家基于RNA干扰（RNAi）技术的生物制药公司，通过RNAi选择性沉默特定基因以治疗多种人类疾病，核心产品包括用于转甲状腺素蛋白淀粉样变性的Amvuttra及Onpattro等。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119455915","title":"异动解读｜阿尔尼拉姆制药公司夜盘上涨5.1%，报340.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119455915","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119455915?lang=zh_cn&edition=full","pubTime":"2026-07-09 14:49","pubTimestamp":1783579782,"startTime":"0","endTime":"0","summary":"7月9日，阿尔尼拉姆制药公司夜盘上涨5.1%，报340.0美元/股，成交额74.26万美元。阿尔尼拉姆制药公司所在的生物科技行业中，个股中，艾伯维公司涨0.0%，福泰制药涨0.19%，吉利德科学跌0.23%，安进跌0.19%，再生元制药公司涨0%。阿尔尼拉姆制药公司是一家基于RNA干扰（RNAi）技术的生物制药公司，通过RNAi选择性沉默特定基因以治疗多种人类疾病，核心产品包括用于转甲状腺素蛋白淀粉样变性的Amvuttra及Onpattro等。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190050017","title":"异动解读｜阿尔尼拉姆制药公司盘中上涨5.01%，多重合作利好叠加生物科技板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1190050017","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190050017?lang=zh_cn&edition=full","pubTime":"2026-07-02 23:00","pubTimestamp":1783004400,"startTime":"0","endTime":"0","summary":"7月2日，阿尔尼拉姆制药公司盘中上涨5.01%，报316.78美元/股，成交额6771.12万美元。多重利好持续释放提振市场情绪。阿尔尼拉姆制药公司是RNA干扰疗法领域的领导者，通过RNAi技术选择性沉默致病基因，开发针对严重疾病的创新治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116794367","title":"异动解读｜阿尔尼拉姆制药公司盘中上涨5.1%，siRNA核心产品销售强劲增长获机构看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1116794367","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116794367?lang=zh_cn&edition=full","pubTime":"2026-06-25 00:51","pubTimestamp":1782319896,"startTime":"0","endTime":"0","summary":"6月25日，阿尔尼拉姆制药公司盘中上涨5.1%，报302.87美元/股，成交额1.55亿美元。消息面上，近期有券商发布深度研报看好公司siRNA药物在心血管赛道的全面布局。相比之下，辉瑞口服药Tafamidis增速已回落至17%，而竞品ASO药物Eplontersen因给药频率较高，上市后放量明显落后。此外，公司在双靶点siRNA等前沿方向的布局也被视为下一个研发热点，进一步巩固其核酸药物龙头地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117880479","title":"Genesis Pharma 与 Alnylam Pharmaceuticals 协议范围扩大，现已覆盖丹麦、芬兰、挪威及瑞典","url":"https://stock-news.laohu8.com/highlight/detail?id=1117880479","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117880479?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:50","pubTimestamp":1781092242,"startTime":"0","endTime":"0","summary":"Genesis Pharma 与阿尔尼拉姆制药公司（Alnylam Pharmaceuticals）的合作协议已获扩展。根据最新安排，协议所覆盖的地域范围现已将丹麦、芬兰、挪威和瑞典四国纳入其中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK4588","BK4585","LU0889565916.HKD","LU0109394709.USD","BK4548","LU0320765992.SGD","BK4139","ALNY","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193311703","title":"创生药业与阿尔尼拉姆制药就RNAi疗法在斯堪的纳维亚地区达成战略商业合作扩展","url":"https://stock-news.laohu8.com/highlight/detail?id=1193311703","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193311703?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:48","pubTimestamp":1781092097,"startTime":"0","endTime":"0","summary":"创生药业宣布，已与阿尔尼拉姆制药公司就RNAi（核糖核酸干扰）疗法达成战略商业合作，并将合作范围扩展至斯堪的纳维亚地区。此举旨在加强双方在该地区的市场覆盖与商业化能力，共同推动创新疗法的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0882574055.USD","BK4139","BK4585","BK4548","BK4588","LU0109394709.USD","LU0114720955.EUR","LU0320765992.SGD","ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180043296","title":"阿尔尼拉姆制药与Inceptive达成战略AI合作，加速RNAi疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1180043296","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180043296?lang=zh_cn&edition=full","pubTime":"2026-06-04 05:57","pubTimestamp":1780523873,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司（Alnylam Pharmaceuticals）与生物技术公司Inceptive宣布建立战略合作，旨在利用人工智能技术加速RNA干扰疗法的发现进程。这项合作潜在总价值高达20亿美元，其中包含3000万美元的预付款。\n通过结合阿尔尼拉姆在RNAi科学领域的深厚专长与Inceptive先进的AI平台，双方将共同探索和开发新型治疗分子。此举有望显著缩短药物研发周期，并为攻克复杂疾病开辟新的可能性。该合作凸显了人工智能在推动下一代生物制药创新中的关键作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4588","LU0882574055.USD","BK4139","LU0889565916.HKD","LU0114720955.EUR","ALNY","BK4585","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":-0.2596},{"period":"3month","weight":-0.2411},{"period":"6month","weight":-0.2829},{"period":"1year","weight":-0.4915},{"period":"ytd","weight":-0.4437}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0207},{"period":"3month","weight":0.0381},{"period":"6month","weight":0.1311},{"period":"1year","weight":0.2117},{"period":"ytd","weight":0.13}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alnylam Pharmaceuticals, Inc.是一家特拉华州公司，成立于2003年5月。该公司是一家研发基于RNA或RNAi干涉为新型治疗手段的生物制药公司。RNAi是一种在生物体内细胞中自然产生的选择性沉默及调控表达的特定基因。由于许多疾病是因为特定基因的不适当活动引起的，通过RNAi对于基因的选择性沉默能力可以为治疗许多人类疾病提供一种新的途径。公司认为，通过RNAi原理工作的药物有潜力成为的一种新的药物分类，诸如小分子药物、蛋白质药物以及抗体药物等。通过已经建立RNAi的知识产权以及专业技术，公司正在开发一套生物化学方法以帮助公司建立一个系统，通过该系统可以研发改进RNAi对于各种疾病的治疗方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.028609},{"month":2,"riseRate":0.454545,"avgChangeRate":0.002754},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.012836},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.021744},{"month":5,"riseRate":0.590909,"avgChangeRate":0.038262},{"month":6,"riseRate":0.608696,"avgChangeRate":0.061553},{"month":7,"riseRate":0.652174,"avgChangeRate":0.088481},{"month":8,"riseRate":0.608696,"avgChangeRate":0.038713},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006257}],"exchange":"NASDAQ","name":"阿尔尼拉姆制药公司","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿尔尼拉姆制药公司,ALNY,阿尔尼拉姆制药公司股票,阿尔尼拉姆制药公司股票老虎,阿尔尼拉姆制药公司股票老虎国际,阿尔尼拉姆制药公司行情,阿尔尼拉姆制药公司股票行情,阿尔尼拉姆制药公司股价,阿尔尼拉姆制药公司股市,阿尔尼拉姆制药公司股票价格,阿尔尼拉姆制药公司股票交易,阿尔尼拉姆制药公司股票购买,阿尔尼拉姆制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}